Bank of America
GLUE icon

Bank of America’s Monte Rosa Therapeutics GLUE Stock Holding History

Bank of America’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.38M Buy
387,542
+163,971
+73% +$3.14M ﹤0.01% 3280
2025
Q4 		$3.51M Sell
223,571
-46,072
-17% -$621K ﹤0.01% 3659
2025
Q3 		$2M Sell
269,643
-1,521
-0.6% -$8.06K ﹤0.01% 4823
2025
Q2 		$1.22M Buy
271,164
+245,119
+941% +$1.09M ﹤0.01% 5157
2025
Q1 		$121K Sell
26,045
-37,238
-59% -$228K ﹤0.01% 6412
2024
Q4 		$439K Sell
63,283
-10,136
-14% -$76.1K ﹤0.01% 5645
2024
Q3 		$389K Buy
73,419
+4,916
+7% +$24.8K ﹤0.01% 5649
2024
Q2 		$256K Buy
68,503
+6,394
+10% +$32.6K ﹤0.01% 5754
2024
Q1 		$438K Sell
62,109
-18,598
-23% -$110K ﹤0.01% 5433
2023
Q4 		$456K Sell
80,707
-893
-1% -$3.5K ﹤0.01% 5560
2023
Q3 		$391K Sell
81,600
-2,462
-3% -$15.9K ﹤0.01% 5485
2023
Q2 		$576K Buy
84,062
+34,140
+68% +$221K ﹤0.01% 5181
2023
Q1 		$389K Sell
49,922
-29,227
-37% -$203K ﹤0.01% 5541
2022
Q4 		$602K Sell
79,149
-27,178
-26% -$226K ﹤0.01% 5236
2022
Q3 		$869K Sell
106,327
-19,913
-16% -$183K ﹤0.01% 4988
2022
Q2 		$1.22M Sell
126,240
-21,434
-15% -$215K ﹤0.01% 4733
2022
Q1 		$2.07M Buy
147,674
+82,018
+125% +$1.14M ﹤0.01% 4557
2021
Q4 		$1.34M Sell
65,656
-13,845
-17% -$290K ﹤0.01% 4961
2021
Q3 		$1.77M Buy
+79,501
New +$2.28M ﹤0.01% 4555

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Bank of America's GLUE Position: Q1 2026 in Review

Bank of America increased its Monte Rosa Therapeutics (GLUE) stake by 73% in Q1 2026, buying an estimated $3.14M and bringing the position to 387,542 shares worth $6.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3280.

Bank of America first reported a position in GLUE in Q3 2021 and has held it in 19 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Bank of America held 387,542 shares of Monte Rosa Therapeutics worth $6.38M as of Q1 2026.
  • Bank of America bought 163,971 Monte Rosa Therapeutics shares in Q1 2026, an estimated $3.14M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3280 holding.
  • Bank of America first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.